AI promises to accelerate the path from bench to bedside. Using CB Insights data, we highlight emerging markets in the preclinical phase that are ripe for pharma investments and partnerships. This is the second report in a 3-part series on how AI is reshaping discovery, preclinical, and clinical research in drug R&D. Read part 1 […]
